hth官方网页版中国有限公司hth官方网页版中国有限公司

0571-87968248 CHINESE
  • Home
  • About us
    ProfileCultureHistory
  • News
    Company newsTrade showsIndustry news
  • Products
    COVID-19 IgG/IgM Rapid Test KitAllergen-specific IgE antibodies test kit seriesFood-specific IgG/IgG4 antibodies test seriesSingle/Polynomial allergen test seriesSingle allergen component test seriesGenetic test for allergic diseases series productsOther seriesProduct specific equipment
  • About allergies
    Scientific literaturePopular scienceVideos
  • Contact us
    Join usContact us
Scientific literaturePopular scienceVideos
Components literatureGene literatureMechanism literatureProbioticsTest literatureDesensitizationOther

Release date:2020-06-05


Allergy                                           
[IF:6.048]
Colony‐stimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma 
DOI: 10.1111/all.14011
Abstract:
Background: A new approach targeting aeroallergen sensing in the early events of mucosal immunity could have greater benefit. The CSF1‐CSF1R pathway has a critical role in trafficking allergens to regional lymph nodes through activating dendritic cells. Intervention in this pathway could prevent allergen sensitization and subsequent Th2 allergic inflammation.
Methods: We adopted a model of chronic asthma induced by a panel of three naturally occurring allergens and novel delivery system of CSF1R inhibitor encapsulated nanoprobe.
Results: Selective depletion of CSF1 in airway epithelial cells abolished the production of allergen‐reactive IgE, resulting in prevention of new asthma development as well as reversal of established allergic lung inflammation. CDPL‐GW nanoprobe containing GW2580, a selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL‐GW nanoprobe ameliorated asthma pathologies including allergen‐specific serum IgE production, allergic lung and airway inflammation and airway hyper‐responsiveness (AHR) with minimal pulmonary adverse reaction.
Conclusion: The inhibition of the CSF1‐CSF1R signaling pathway effectively suppresses sensitization to aeroallergens and consequent allergic lung inflammation in a murine model of chronic asthma. CSF1R inhibition is a promising new target for the treatment of allergic asthma.
First Author:
Hyung‐Geun Moon
Correspondence:
Hyung‐Geun Moon and Gye Young Park,Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago,840 S. Wood St. CSB‐920N, Chicago, IL 60612, USA.
All Authors:
Hyung‐Geun Moon, Seung‐jae Kim, Myoung Kyu Lee, Homan Kang, Hak Soo Choi, Anantha Harijith, Jinhong Ren, Viswanathan Natarajan, John W. Christman, Steven J. Ackerman, Gye Young Park
2020-06-15  Article
  • Home
  • About us
  • News
  • Products
  • About allergies
  • Contact us
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.  Copyright    HZKC Technical support   浙ICP备14005341号   (浙)-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist.      Tel: 0571-87968248-805     Website:www.szzyfzls.com

COPYRIGHT©2003-2024 www.szzyfzls.com CORPORATION. ALL RIGHTS RESERVED

Official WeChat

乐动网页版 | 江南游戏 | 开云在线登录 | 江南游戏 | 开云电子(中国)有限公司官网 | 乐竞网页版登录入口 | 九州平台 | 冠盈体育(中国)科技有限公司官网 | 乐动手机网页版登录入口 |